Lifeboat Foundation

Norway has installed the world’s northernmost solar farm and battery storage in the Svalbard archipelago, just south of the North Pole.

State-owned energy company Store Norske Energi installed the solar and storage at Isfjord Radio on the island of Spitsbergen, the largest and the only permanently populated island in the archipelago, and the solar farm is expected to come online tomorrow.

Isfjord was built as a radio station in 1933 to provide a communication link between the Svalbard archipelago and Norway’s mainland. It’s still a radio station and a weather station, and now there’s a hotel for tourists and researchers.

Beguš is a linguist at the University of California, Berkeley. He got the chance, last summer, to observe sperm whales in their wild Caribbean habitat off the coast of the island nation of Dominica. With him were marine biologists and roboticists. There were also cryptographers and experts in other fields. All have been working together to listen to sperm whales and figure out what they might be saying.

They call this Project CETI. That’s short for Cetacean Translation Initiative (because sperm whales are a type of cetacean).

Continue reading “How artificial intelligence could help us talk to animals” »

Here is another story from web bike world: “Is water the future of motorbikes”

https://www.webbikeworld.com/water-power-future-motorbikes/

Continue reading “Motorcycle Goes 300 Miles on 1 Liter of Water” »

Wildfires fueled by climate change have ravaged communities from Maui to the Mediterranean this summer, killing many people, exhausting firefighters and fueling demand for new solutions. Enter artificial intelligence.

Firefighters and startups are using AI-enabled cameras to scan the horizon for signs of smoke. A German company is building a constellation of satellites to detect fires from space. And Microsoft is using AI models to predict where the next blaze could be sparked.

With wildfires becoming larger and more intense as the world warms, firefighters, utilities and governments are scrambling to get ahead of the flames by tapping into the latest AI technology—which has stirred both fear and excitement for its potential to transform life. While increasingly stretched first responders hope AI offers them a leg up, humans are still needed to check that the tech is accurate.

“That’s what makes this research unique from a scientific standpoint. The study participant can walk over to the lab, have the blood drawn and within hours their specimen can be transferred to the on-site facility where the process of biomanufacturing the vaccine begins,” says Dr. Block. “That would not be possible with an outside manufacturer.”

A deadly form of reproductive system cancer

Ovarian cancer is the deadliest form of gynecologic cancer. It often is not diagnosed until advanced stages, when it is less treatable. Even with standard surgery and chemotherapy, tumors return in up to 70% of women. The outcome is often poor. 19,000 women in the U.S. are diagnosed with ovarian cancer every year and more than 13,000 die from it, according to the American Cancer Society.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
Oral Microbiome: https://www.bristlehealth.com/?ref=michaellustgarten.
Enter Code: ConquerAging.

Continue reading “Albumin, CRP, and Creatinine: Better Markers Of Longevity Than Lipoproteins And Glycemic Status” »

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

Patients treated with fixed-duration ibrutinib (Imbruvica) plus venetoclax (Venclexta) achieved higher undetectable minimal residual disease (uMRD), progression-free survival (PFS), and overall survival (OS) rates compared with chlorambucil plus obinutuzumab (Gazyva) across most genomic subgroups of chronic lymphocytic leukemia (CLL).1.

Findings come from the phase 3 GLOW study (NCT03462719) in which data were presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). Patients treated with ibrutinib and venetoclax achieved a higher uMRD rate at 3 months (54.7%) after the end of treatment compared with patients treated with obinutuzumab and chlorambucil (39.0%), except patients with trisomy-12, IGLL5 mutation, and mutated immunoglobulin heavy-chain variable (mIGHV).

Astronomers say they have spotted evidence of stars fuelled by the annihilation of dark matter particles. If true, it could solve the cosmic mystery of how supermassive black holes appeared so early.

By Jonathan O’Callaghan